Didier Leys

In a recent study, rivaroxaban was not superior to aspirin for secondary prevention of stroke and systemic emboli after an initial embolic stroke of undetermined source (ESUS) but was associated with a higher risk of bleeding. What does that mean for the concept of ESUS and for future trials?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00 Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Intravenous Recombinant Tissue-Type Plasminogen Activator Marc Ferrigno, Nicolas Bricout, Didier Leys, Laurent Estrade, Charlotte Cordonnier, Thomas Personnic, Maeva Kyheng and Hilde Henon